Intellia collaborates on the development of CRISPR gene editing therapy to treat blinding eye disease

On October 13, 2021, Intellia Therapeutics and SparingVision jointly announced that the two parties have reached a strategic cooperation to jointly develop new gene editing therapies based on CRISPR/Cas9 technology to treat ophthalmic diseases

Professor Emmanuelle Charpentier and Professor Jennifer Doudna, pioneers of CRISPR gene editing research, won the Nobel Prize in Chemistry last year

SparingVision is committed to the development of gene therapy for the treatment of retinitis pigmentosa

As part of this collaboration, SparingVision will obtain the exclusive rights to use Intellia's proprietary CRISPR/Cas9 in vivo genome editing technology for up to 3 ocular targets to treat diseases with significant unmet medical needs

Reference materials:

[1] Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology.

(The original text has been deleted)